Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


SCCA Breast Cancer Clinical Trials

PET (F-18) Bone Mets (6337)
Positron Emission Tomography (PET) for Evaluation of Breast Cancer Metastases to Bone with [F-18] Fluoride
Status Conditions Phase Study ID
Closed Breast Cancer N/A 6337
Summary

The aim of this study is to learn more about breast cancer that has spread to the bones, known as bone metastases. In this study we will use [F-18] Fluoride, an approved radioactive tracer with positron emission tomography (PET) to visualize response of bone disease and normal bone to treatment. Positron emission tomography (PET) is a type of radiologic scan that uses a large donut shaped detection device to pick up tiny radiation signals given off by a radioactive tracer. [F-18] Fluoride concentrates in the parts of the body where normal bone is growing or where bone metastases are disturbing normal bone; making it a more sensitive measure of bone turnover compared to conventional bone scanning. The purpose of this study is to use [F-18] Fluoride PET as a sophisticated method of evaluating bone turnover and quantifying bone metastasis response to treatment.

All participants will first undergo a baseline research [F-18] Fluoride PET scan at either the Seattle Cancer Care Alliance (SCCA) or the University of Washington Medical Center (UWMC) before starting their new therapy as prescribed by their medical oncologist. After a set time period of treatment (2-3 months on chemotherapy or 4-6 months on endocrine therapy) the participant will undergo a repeat research [F-18] Fluoride PET at the same institution where the baseline scan was performed. In addition, we will ask permission to review your medical records for up to ten years following the repeat [F-18] Fluoride PET.


Investigator
David Mankoff, M.D., PhD
Location    
SCCA Breast Cancer Clinical Trials Program 800-804-8824 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)

DISEASE CHARACTERISTICS:
Inclusion criteria
• Documented breast cancer metastases to bone
Bone disease must be documented by bone biopsy or clear diagnostic findings on at least two standard imaging modalities (bone scan, CT, MRI or FDG PET/CT)

PATIENT CHARACTERISTICS:
Inclusion criteria
• Willing to undergo repeat imaging studies at periodic intervals
• Starting new systemic endocrine therapy or chemotherapy
 

Exclusions (conditions that would prevent participation in this study)

DISEASE CHARACTERISTICS:

• History of malignancy other than breast cancer or non-melanoma skin cancer
• Significant soft tissue metastases (eg: lung, liver or lymph nodes) or a history of previous extensive XRT or surgery for bone metastases

PATIENT CHARACTERISTICS:

• Pregnant or lactating
• Uncontrolled diabetes mellitus
• Has serious systemic illness other than breast cancer
• Inability to tolerate scanning (e.g. - claustrophobia, severe pain).
 

Last Updated
May 09, 2013
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.